Michael Cherny Analyst PerformanceSenior Managing Director / Healthcare Technology & Distribution Equity Research Analyst at Leerink PartnersMichael Cherny is a stock analyst at Leerink Partners focused in the medical sector, covering 22 publicly traded companies. Over the past year, Michael Cherny has issued 35 stock ratings, including buy, hold, and sell recommendations. While full access to Michael Cherny's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Michael Cherny's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings69 Last 11 YearsBuy Recommendations70.31% 45 Buy RatingsCompanies Covered22 Unique Companies Ratings Distribution64RatingsDistribution of strong buy, buy, hold, and sell ratings by Michael Cherny.RatingPercentageCount Strong Buy0.0%0 ratings Buy70.3%45 ratings Hold23.4%15 ratings Sell6.3%4 ratingsOut of 64 total stock ratings issued by Michael Cherny at Leerink Partners, the majority (70.3%) have been Buy recommendations, followed by 23.4% Hold and 6.3% Sell.Best & Worst CallsBest Call000.0%CAHApr 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%DOCSFeb 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ54.5% of companies on NASDAQ12 companiesNYSE40.9% of companies on NYSE9 companiesOTCMKTS4.5% of companies on OTCMKTS1 companyMichael Cherny, an analyst at Leerink Partners, currently covers 22 companies listed on NASDAQ, NYSE and OTCMKTS, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical17 companies77.3%Services1 company4.5%Manufacturing1 company4.5%Retail/Wholesale1 company4.5%Business Services1 company4.5%Miscellaneous1 company4.5%Michael Cherny of Leerink Partners specializes in stock coverage within the Medical sector, with additional focus on Services and Manufacturing companies.Coverage IndustriesIndustryPercentageMEDICAL SERVICES8 companies36.4%MED/DENTAL - SUPP4 companies18.2%SERVICES – COMPUTER PROGRAMMING AND DATA PROCESSING1 company4.5%MEDICAL INFO SYS1 company4.5%MED - BIOMED/GENE1 company4.5%SURGICAL, MEDICAL, AND DENTAL INSTRUMENTS AND SUPPLIES1 company4.5%MED - OUTP/HM CRE1 company4.5%PHARMACEUTICAL PREPARATIONS1 company4.5%MED PRODUCTS1 company4.5%RETAIL - DRUG STR1 company4.5%COMPUTER INTEGRATED SYSTEMS DESIGN1 company4.5%HOLDING & OTHER INVESTMENT OFFICES1 company4.5% About Michael ChernyMichael Cherny is a Senior Managing Director and Senior Research Analyst at Leerink Partners covering Healthcare Technology and Distribution. Prior to joining the Firm in 2023, Michael’s most recent role was at Bank of America Merrill Lynch where he was Managing Director / Healthcare Technology & Distribution Analyst. Prior to Bank of America Merrill Lynch, Michael was the Healthcare Technology & Distribution Analyst at UBS Securities and held roles at Evercore ISI and Deutsche Bank within the healthcare and technology sector. Michael has been consistently ranked in the Extel survey (formerly Institutional Investor) for the Health Care Technology & Distribution group since 2019, including being ranked #1 in 2022-2023. He earned his bachelor’s degree in business administration from Emory University.Follow on LinkedIn Michael Cherny's Ratings History at Leerink Partners Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsDOCSDoximity5/14/2026Lower Price Target$23.52$25.00Outperform$0.0000.00% ROIICLRIcon5/4/2026Set Price Target$112.85$125.00$0.0000.00% ROIMCKMcKesson4/6/2026Lower Price Target$859.91$1,000.00Buy$0.0000.00% ROIHIMSHims & Hers Health3/16/2026Boost Price Target$24.73$25.00Market Perform$0.0000.00% ROICAHCardinal Health3/9/2026Reiterated Rating$222.30$275.00Outperform$0.0000.00% ROIHSICHenry Schein3/9/2026Reiterated Rating$78.09Market Perform$0.0000.00% ROICVSCVS Health3/5/2026Reiterated Rating$79.30$98.00Outperform$0.0000.00% ROIMCKMcKesson3/5/2026Reiterated Rating$930.50$1,085.00Outperform$0.0000.00% ROICAHCardinal Health3/2/2026Boost Price Target$231.52$275.00Outperform$0.0000.00% ROICERTCertara2/26/2026Reiterated Rating$6.39$10.00Outperform$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. GDRXGoodRx2/26/2026Reiterated Rating$2.04$3.00Outperform$0.0000.00% ROITDOCTeladoc Health2/26/2026Lower Price Target$5.44$5.50Market Perform$0.0000.00% ROIMDLNMedline2/25/2026Set Price Target$48.64$56.00$0.0000.00% ROIHIMSHims & Hers Health2/24/2026Lower Price Target$15.47$17.50Market Perform$0.0000.00% ROIHSICHenry Schein2/24/2026Boost Price Target$84.08$87.00Market Perform$0.0000.00% ROIXRAYDENTSPLY SIRONA2/19/2026Upgrade$12.49$17.00Buy$0.0000.00% ROIICLRIcon2/12/2026Reiterated Rating$133.14$105.00Market Perform$0.0000.00% ROIMEDPMedpace2/11/2026Lower Price Target$446.05$485.00Market Perform$0.0000.00% ROICAHCardinal Health2/5/2026Boost Price Target$227.30$268.00Outperform$0.0000.00% ROICVSCVS Health1/27/2026Lower Price Target$75.05$95.00Buy$0.0000.00% ROICAHCardinal Health1/13/2026Set Price Target$208.08$240.00$0.0000.00% ROIMDLNMedline1/12/2026Initiated Coverage$40.52$48.00Outperform$0.0000.00% ROICAHCardinal Health11/17/2025Boost Price Target$204.53$230.00Outperform$0.0000.00% ROICAHCardinal Health10/31/2025Boost Price Target$190.65$211.00$0.0000.00% ROIDGXQuest Diagnostics10/21/2025Boost Price Target$184.75$210.00Outperform$0.0000.00% ROICAHCardinal Health10/6/2025Boost Price Target$154.48$187.00Outperform$0.0000.00% ROIMCKMcKesson9/24/2025Boost Price Target$739.48$850.00Buy$0.0000.00% ROIMCKMcKesson9/24/2025Boost Price Target$739.48$850.00Outperform$0.0000.00% ROIPINCPremier8/19/2025Boost Price Target$26.83$26.00Market Perform$0.0000.00% ROIPINCPremier8/19/2025Boost Price Target$26.39$21.00Underperform$0.0000.00% ROICAHCardinal Health8/12/2025Lower Price Target$146.51$186.00Outperform$0.0000.00% ROIHSICHenry Schein7/14/2025Set Price Target$70.46$75.00$0.0000.00% ROIPGNYProgyny7/8/2025Upgrade$24.18$28.00Outperform$0.0000.00% ROICAHCardinal Health6/10/2025Boost Price Target$153.64$170.00Buy$0.0000.00% ROIBOLDBoundless Bio5/28/2025Downgrade$1.30$3.00Market Perform$0.0000.00% ROIMCKMcKesson5/9/2025Boost Price Target$694.98$800.00Buy$000.0000.00% ROINVSTEnvista4/29/2025Lower Price Target$16.25$23.00Buy$00.0000.00% ROIMCKMcKesson4/11/2025Boost Price Target$678.08$755.00Buy$000.0000.00% ROICAHCardinal Health4/11/2025Boost Price Target$129.00$155.00Buy$000.0000.00% ROIMEDPMedpace3/24/2025Initiated Coverage$324.23$330.00Market Perform$000.0000.00% ROIYour book attached (Ad)Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.Download the Safe Trade Options Formula book for free before access closesHIMSHims & Hers Health2/25/2025Boost Price Target$38.71$40.00Market Perform$00.0000.00% ROICVSCVS Health2/13/2025Upgrade$63.23$75.00Outperform$00.0000.00% ROIPGNYProgyny2/11/2025Boost Price Target$22.35$25.00Buy$00.0000.00% ROIDOCSDoximity2/7/2025Upgrade$58.58$90.00Outperform$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel NicolausRaymond James Financial Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
